Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:Assertio (ASRT) is a specialty pharmaceutical company with branded prescription neurology, inflammation and pain medications. The Zacks Consensus Estimate for its current year earnings has been revised 83.3% downward over the last 60 days.Bridgeline Digital (BLIN) is a digital engagement company which provides platform that integrates Web Content Management, e-commerce, e-marketing, Social Media management and Web Analytics. The Zacks ...

Sustainable Long-Term Growth from Commercial Pharmaceutical Assets Nasdaq: ASRT May 2025 Disclaimers The statements in this communication include forward-looking statements. Forward-looking statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs. Forward-looking statements speak only as of the date they are made or as of the dates indicated in the statements and should not be relied upo ...

Assertio Holdings (ASRT) Conference Summary Company Overview - Assertio Holdings is a specialty pharmaceuticals company with a market cap of approximately $70 million and shares trading at around 70¢ [2][4] - The company is focused on long-term growth and has a leadership team with extensive commercial experience in various therapeutic areas [5][6] Core Assets and Financial Performance - Assertio's core assets include Rovidone and SYMPAZAN, with Rovidone being a novel long-acting G-CSF approved in the last twenty years, targeting a market worth about $1 billion [8][9] - The company reported net sales of $26 million for the first quarter and maintains a positive adjusted EBITDA with a cash balance of nearly $90 million [9] - The financial outlook for the year includes projected net sales of $108 to $123 million and non-GAAP EBITDA of $10 to $20 million [10] Transformation and Growth Strategy - The company is in a transformation phase, simplifying its corporate structure and optimizing its asset portfolio, focusing on growth assets like Rovidone and SYMPAZAN [12][15] - Assertio aims to reduce legal exposure, which will allow for reinvestment into the business and positively impact EBITDA [13][14] - Business development is seen as a key enabler for future growth, with a focus on oncology, neurology, and rare diseases [14] Product Insights - Rovidone contributes over half of the total net sales and is expected to grow modestly this year, with plans to expand into the commercial segment by 2026 [19][21] - SYMPAZAN, an oral film formulation for Lennox Gastaut syndrome, is projected to grow to $13 million this year and has the potential to reach $25 million in the coming years [28] Competitive Landscape - The market for white blood cell stimulants is competitive, with Rovidone competing against biosimilars like Neulasta. Assertio is focused on managing average selling prices (ASP) smartly to sustain growth [23][24] Legal and Operational Improvements - Assertio has successfully reduced its litigation overhead, particularly related to opioid litigation, which has allowed for a cleaner balance sheet and operational focus [36][38] - The company has divested certain assets to streamline operations and eliminate legal distractions [38] Future Outlook - The CEO expressed optimism about the company's trajectory, aiming for significant growth and improved operational efficiency over the next year [41][42] - Assertio is positioned to explore mergers and acquisitions to enhance its portfolio, supported by a strong balance sheet with $40 million in convertible debt due in 2027 [34][35] Key Takeaways - Assertio is undergoing a transformation aimed at growth, with a focus on optimizing its asset portfolio and reducing legal distractions [12][15] - The company has a solid financial outlook and is strategically positioned to capitalize on growth opportunities in specialty pharmaceuticals [10][14] - Assertio's leadership is optimistic about future performance, with plans to enhance product offerings and expand market presence [41][42]

Core Viewpoint - Assertio Holdings, Inc. will be presenting at the virtual Alliance Global Partners Healthcare Company Showcase on May 21, 2025, highlighting its focus on patient needs in the pharmaceutical sector [1]. Company Overview - Assertio is a pharmaceutical company with comprehensive commercial capabilities, offering differentiated products aimed at addressing patients' needs [3]. - The company's primary focus areas include oncology, neurology, and pain management [3]. Event Details - Brendan O'Grady, the CEO of Assertio, will participate in a fireside chat that will be webcast live at 11:20 a.m. ET [2]. - Interested participants can register for the event through a provided link or visit the company's investor relations website [2].

Core Insights - Assertio (ASRT) reported a quarterly loss of $0.14 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.06, marking an earnings surprise of -133.33% [1] - The company's revenues for the quarter ended March 2025 were $26.49 million, missing the Zacks Consensus Estimate by 5.23% and down from $32.45 million a year ago [2] - Assertio shares have declined approximately 30% year-to-date, contrasting with the S&P 500's decline of -3.8% [3] Financial Performance - Over the last four quarters, Assertio has surpassed consensus EPS estimates only once [2] - The current consensus EPS estimate for the upcoming quarter is -$0.06 on revenues of $27.54 million, and for the current fiscal year, it is -$0.12 on revenues of $116.78 million [7] Market Outlook - The estimate revisions trend for Assertio is currently unfavorable, resulting in a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [6] - The Medical - Drugs industry, to which Assertio belongs, is ranked in the top 27% of over 250 Zacks industries, suggesting a favorable industry outlook [8]

Assertio (ASRT) Q1 2025 Earnings Call May 12, 2025 04:30 PM ET Company Participants Matthew Kreps - Managing DirectorBrendan O’Grady - CEORaghuram Selvaraju - Managing Director, Healthcare Equity Research Conference Call Participants Thomas Flaten - Senior Research AnalystNaz Rahman - AnalystScott Henry - Managing Director & Senior Research AnalystJim Sidoti - Analyst Operator Good day, ladies and gentlemen. Welcome to the Associal Holdings First Quarter twenty twenty five Results Conference Call. Just a re ...

Financial Data and Key Metrics Changes - In Q1 2025, net product sales were $26 million, slightly ahead of expectations, compared to $31.9 million in the prior year quarter [5][13] - Adjusted EBITDA for Q1 was $200,000, down from $7.4 million in the prior year quarter, primarily due to lower net sales and gross margin [16] - GAAP net income for Q1 was a loss of $13.5 million, compared to a loss of $4.5 million in the prior year [16] Business Line Data and Key Metrics Changes - ROLVOIDON sales were $13.1 million, down from $14.5 million in the prior year, impacted by lower pricing but partially offset by higher volume [13] - SYMPAZAN sales decreased to $2.2 million from $2.6 million, affected by pricing and volume [14] - Indocin net product sales were $5.5 million, down from $8.7 million, due to generic competition [13] Market Data and Key Metrics Changes - The demand for ROLVOIDON remains strong, with expectations for net sales to continue increasing throughout the year [6] - The promotional strategy for SYMPAZAN has shown effectiveness, with total prescriptions up 6.5% year over year [6] Company Strategy and Development Direction - The company is in the transformation phase of its three-phase strategy, focusing on reducing legal exposure, simplifying corporate structure, prioritizing growth investments, divesting non-core assets, and leveraging its balance sheet for strategic transactions [8][9] - The growth phase is expected to begin in 2026, aiming to establish the company as a leading specialty pharma entity [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving sustainable near-term growth and increasing long-term value, despite challenges from generic competition and pricing pressures [18] - The company is optimistic about ongoing conversations for strategic transactions that could enhance its business [44] Other Important Information - The company has settled multiple legal matters, including significant lawsuits, which is expected to reduce legal costs and refocus resources on business operations [9][10] - As of March 31, 2025, cash and investments totaled $87.3 million, down from $100.1 million at the end of 2024 [16] Q&A Session Summary Question: Was there any value movement regarding the opioid litigation matters? - The company received nominal value in the settlement [20] Question: How should cash be used to bring down accrued liabilities? - The company expects to manage this relatively evenly throughout the year, primarily driven by ROLVOIDON's ASP-based pricing [21] Question: Any updates on same-day dosing progress with NCCN? - The company is on track for a publication in a peer-reviewed journal and plans to approach NCCN for inclusion in guidelines for 2026 [23][24] Question: Progress on expanding ROLVOIDON into the hospital setting? - The company is focusing on building payer coverage to unlock commercial channels and penetrate hospitals [29] Question: Why maintain the adjusted EBITDA guidance despite Q1 results? - The company believes there are still too many variables to adjust the guidance down at this time [30] Question: Expectations for Indocin's generic competition? - The company anticipates two more generics entering the market this year, which will impact revenue [39] Question: Any updates on strategic business development opportunities? - The company is optimistic about ongoing positive conversations for potential strategic transactions in 2025 [44] Question: Impact of tariffs and drug pricing changes? - The company does not foresee immediate risks from tariffs or drug pricing changes, as it primarily sells within the U.S. [57][59] Question: Confirmation of revenue guidance post-divestiture? - The company confirmed it is maintaining its revenue guidance of $108 million to $122 million [61]

Financial Performance - ROLVEDON net product sales decreased by $1.4 million from $14.5 million in Q1 2024 to $13.1 million in Q1 2025, primarily due to lower net pricing, partially offset by higher volume [125]. - Total revenues for Q1 2025 were $26.5 million, down from $32.4 million in Q1 2024, reflecting a decrease of approximately 18.2% [124]. - Loss from operations increased to $13.2 million in Q1 2025 compared to a loss of $4.3 million in Q1 2024 [124]. - INDOCIN net product sales decreased by $3.1 million from $8.7 million in Q1 2024 to $5.5 million in Q1 2025 due to lower volume and pricing from generic competition [126]. - Sympazan net product sales decreased by $0.4 million from $2.6 million in Q1 2024 to $2.2 million in Q1 2025, primarily due to unfavorable payor mix and lower volume [127]. Expenses - Cost of sales decreased from $11.2 million in Q1 2024 to $7.8 million in Q1 2025, a reduction of approximately 30.0% [124]. - Selling, general and administrative expenses rose to $22.0 million in Q1 2025 from $18.5 million in Q1 2024, an increase of approximately 19.8% [124]. - Amortization of intangible assets increased significantly from $5.6 million in Q1 2024 to $9.2 million in Q1 2025, reflecting a rise of approximately 63.5% [124]. - Research and development expenses were $0.4 million in Q1 2025, down from $0.7 million in Q1 2024, reflecting reduced costs associated with ongoing clinical activity for ROLVEDON [134]. - Selling, general and administrative expenses increased by $3.5 million from $18.5 million in Q1 2024 to $22.0 million in Q1 2025, driven by higher legal charges [136]. - Amortization of intangible assets increased by $3.6 million from $5.6 million in Q1 2024 to $9.2 million in Q1 2025, primarily due to changes in estimated useful lives of ROLVEDON and INDOCIN [137]. Cash Flow and Working Capital - Cash and cash equivalents totaled $87.3 million as of March 31, 2025, expected to be sufficient for operations and debt payments over the next 12 months [146]. - Net cash used in operating activities was $12.5 million in Q1 2025, compared to net cash provided of $7.5 million in Q1 2024 [151]. - Cash used in operating activities was $12.5 million for Q1 2025, a decrease from cash provided of $7.5 million in Q1 2024, primarily due to lower net product sales and higher expenses [152]. - Net working capital was a net use of cash of $10.1 million in Q1 2025, compared to a net cash provided of $3.6 million in Q1 2024, reflecting a $13.7 million change [152]. - Cash used in investing activities was $2.9 million in Q1 2025, consisting of $31.4 million in purchases of short-term investments, offset by $28.5 million from maturities [155]. - Cash used in financing activities was $0.1 million in Q1 2025, slightly down from $0.2 million in Q1 2024, related to employee stock awards [156]. Tax and Accounting - The company recorded an income tax expense of $0.2 million in Q1 2025, compared to $0.1 million in Q1 2024, with a full valuation allowance against net deferred tax assets [144]. - There were no material changes to the company's cash requirements from contractual obligations since the last filing [157]. - Critical accounting policies related to revenue recognition and impairment of long-lived assets remain unchanged since the last filing [158]. - The company is classified as a smaller reporting company and is not required to provide additional market risk disclosures [159]. Product and Market Strategy - ROLVEDON is indicated to decrease the incidence of infection in adult patients receiving anti-cancer drugs, targeting both hospitals and community oncology clinics [118]. - The company acquired ROLVEDON through a merger with Spectrum Pharmaceuticals on July 31, 2023, enhancing its product portfolio [118]. - The company is focusing on expanding its commercial capabilities through a patient-centric approach and omni-channel promotional model [121]. - The company anticipates that the average sales price for ROLVEDON will be negatively impacted in the remainder of 2025 due to increased discounts and rebates [125]. Restructuring - Restructuring charges were $0.3 million in Q1 2025, down from $0.7 million in Q1 2024, related to efficiency improvements in the sales and marketing department [141].

Financial Performance - Total net product sales for the first quarter of 2025 were $26.0 million, down from $31.9 million in the same quarter of 2024, reflecting a decrease of approximately 18.3% year-over-year[5] - Rolvedon net sales were $13.1 million, a decrease from $14.5 million in the prior year quarter, driven by lower pricing, partially offset by higher volume[8] - Indocin net product sales were $5.5 million, down from $8.7 million in the prior year quarter, due to generic competition affecting both volume and pricing[8] - The company reported a net loss of $13.5 million for the first quarter of 2025, compared to a net loss of $4.5 million in the same quarter of 2024[5] - Adjusted EBITDA for the first quarter was $0.2 million, a significant decrease from $7.4 million in the prior year quarter, primarily reflecting lower net product sales[8] - Adjusted EBITDA for the three months ended March 31, 2025, was $158,000, down from $7,379,000 in the same period of 2024, showing a decline of approximately 97.9%[22] Expenses and Costs - Selling, general and administrative expenses increased to $22.0 million from $18.5 million in the prior year quarter, primarily due to higher legal charges[8] - The company incurred stock-based compensation expenses of $1,101,000 for the three months ended March 31, 2025, slightly down from $1,207,000 in the same period of 2024[22] Cash and Investments - Cash, cash equivalents, and short-term investments totaled $87.3 million as of March 31, 2025, down from $100.1 million as of December 31, 2024[8] - Cash and cash equivalents decreased to $35,004,000 at the end of the period, down from $50,588,000 at the beginning of the year, representing a decrease of about 30.7%[21] - The company reported a net cash used in operating activities of $12,538,000 for the three months ended March 31, 2025, compared to net cash provided of $7,508,000 in the same period of 2024[21] Assets and Liabilities - Total current assets increased to $213,550,000 as of March 31, 2025, up from $202,549,000 as of December 31, 2024, reflecting a growth of about 5.0%[19] - Total liabilities rose to $177,896,000 as of March 31, 2025, compared to $163,651,000 as of December 31, 2024, indicating an increase of approximately 8.7%[19] - The company’s total current liabilities increased to $128,832,000 as of March 31, 2025, compared to $114,688,000 as of December 31, 2024, indicating an increase of approximately 12.3%[19] - The total shareholders' equity decreased to $108,530,000 as of March 31, 2025, down from $121,081,000 as of December 31, 2024, reflecting a decline of about 10.4%[19] Strategic Focus - The company is prioritizing investment in growth assets and divesting declining or non-core assets as part of its long-term business strategy[2] - The company has settled multiple legal matters, reducing future legal costs and focusing resources on the business[4] Accounts Receivable - The company experienced a significant increase in accounts receivable, net, which rose to $66,292,000 as of March 31, 2025, compared to $54,120,000 as of December 31, 2024, marking an increase of approximately 22.5%[19]

Core Insights - Assertio Holdings, Inc. reported first quarter total net product sales of $26.0 million, aligning with its 2025 outlook for sustainable growth and increased long-term value [1][2] - The company is focused on reducing legal exposure, simplifying corporate structure, prioritizing growth investments, and divesting non-core assets as part of its transformation strategy [2][5] Financial Performance - Net sales for the first quarter were $26.0 million, down from $31.9 million in the same quarter last year, with a net loss of $13.5 million compared to a loss of $4.5 million in the prior year [4][11] - Adjusted EBITDA was $0.2 million, significantly lower than $7.4 million in the previous year, primarily due to decreased net product sales and increased costs associated with higher Rolvedon volumes [4][11] - Rolvedon net sales were $13.1 million, a decrease from $14.5 million year-over-year, while Sympazan prescriptions increased by 6.5% year-over-year [3][11] Legal and Corporate Developments - The company settled multiple legal matters, including a DOJ False Claims Act lawsuit and an antitrust action, which is expected to reduce future legal costs [5] - Assertio has begun simplifying its corporate structure by transferring interests in its subsidiary Assertio Therapeutics, which held approximately $8.2 million in cash and certain legal liabilities [5] Balance Sheet and Cash Flow - As of March 31, 2025, Assertio had cash, cash equivalents, and short-term investments totaling $87.3 million, down from $100.1 million at the end of 2024 [12] - The company reported a net cash used in operating activities of $12.5 million for the quarter, compared to a net cash provided of $7.5 million in the same period last year [22] Strategic Focus - Assertio is reallocating resources to focus on growth assets, particularly Rolvedon and Sympazan, while progressing towards divesting non-core assets [5][11] - The management plans to host a conference call to discuss the financial results and provide further details on the corporate strategy for 2025 [7]